Matches in Nanopublications for { ?s ?p "[Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 9 of
9
with 100 items per page.
- assertion description "[Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP24548.RA63j_w2MM-b4ii6nyN4wbV7DxRi1iF9PbGhTfc8r3ZDM130_assertion description "[Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP24548.RA63j_w2MM-b4ii6nyN4wbV7DxRi1iF9PbGhTfc8r3ZDM130_provenance.
- NP8039.RA7qrBsUyXwe-2AR6QffPMQ_E-GiWZsHdaUPqVNi_hmw0130_assertion description "[Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP8039.RA7qrBsUyXwe-2AR6QffPMQ_E-GiWZsHdaUPqVNi_hmw0130_provenance.
- assertion description "[Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP24277.RAO4Voyyuj7y93tJha7_vyUKJt4XLuF2pLtRXYeR9uDq8130_assertion description "[Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP24277.RAO4Voyyuj7y93tJha7_vyUKJt4XLuF2pLtRXYeR9uDq8130_provenance.
- NP14900.RAC45_F_yoB4acKPVe4WAwlXMr-Okmbd9Xv9ygT1iXp2E130_assertion description "[Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP14900.RAC45_F_yoB4acKPVe4WAwlXMr-Okmbd9Xv9ygT1iXp2E130_provenance.
- NP6243.RAKwmVCHMjRYans2tdKUjHXHFWi5zP7CGXXvLrH9lni-E130_assertion description "[Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP6243.RAKwmVCHMjRYans2tdKUjHXHFWi5zP7CGXXvLrH9lni-E130_provenance.
- NP14899.RA705jHK0kF6pqW12b7HKM8gDWXzx_oRkAizGi4b_WVMY130_assertion description "[Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP14899.RA705jHK0kF6pqW12b7HKM8gDWXzx_oRkAizGi4b_WVMY130_provenance.
- NP14901.RA_Ya8nDdkm7Kxhd45Jmg5d-zoxseokZZpvhwUsIFudcA130_assertion description "[Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP14901.RA_Ya8nDdkm7Kxhd45Jmg5d-zoxseokZZpvhwUsIFudcA130_provenance.